UNH•UNH•Bank of America upgraded UnitedHealth to Buy and raised its price target to $450 from $420, citing improving medical cost trends and a favorable second-quarter earnings setup. The firm used a 21.4x multiple on 2027 estimates, utilization data and forecasts earnings above $26 per share if margins recover by 2028.
Bank of America upgraded UnitedHealth to Buy, raising its price target from $420 to $450 and highlighting an attractive risk/reward profile ahead of second-quarter earnings. The shift from Neutral to Buy reflects heightened confidence in the insurer’s valuation relative to peers.
The upgrade was supported by moderating medical cost trends identified through utilization data and commentary from healthcare providers, noting weak April and May patient volumes that suggest ongoing expense control. These signals underpin expectations for normalized cost patterns into the summer quarter.
Analysts estimate UnitedHealth’s earnings power at roughly 50% above its 2026 guidance, projecting earnings north of $26 per share if the company returns to target margins by 2028. Medium-term headwinds include Medicare Advantage star ratings and rate proposal uncertainties that could pressure future profitability.
UnitedHealth shares rose 2.7% in premarket trading, aiming to end a five-day losing streak, with a 14-day RSI at 25.5 indicating oversold conditions. Options markets reflect low implied volatility at 31%, yet the stock’s volatility scorecard ranks in the top quartile for exceeded expectations over the past year.
Marketwatch
